The MYC protein plays an important role in the development of many types of cancer in humans. Among other things, it is involved in leukaemia and neuroblastoma, two of the most common types of cancer in children.
The MYC gene has normal functions in regulating cell growth, but can cause cancer if it becomes overactive. Despite enormous efforts, suitable strategies for inhibiting MYC in cancer are still in their infancy.
The ‘single project’ now funded by the FWF, led by Dr Davide Seruggia at St. Anna Children’s Cancer Research, aims to curb the carcinogenic overactivity of MYC.
To achieve this, the researchers are taking a very close look at the SAGA protein complex, as it influences both the production and activity of MYC.
“We are characterising key components of the SAGA complex to identify the areas most critical to cancer development. Such areas could serve as targets for new drugs to treat MYC-driven cancers,” explains Seruggia.
Seruggia compares the study of the SAGA complex and how it can be specifically targeted to taking a car engine apart: “First, we are looking for genetic mutations in all 20 parts of the engine, with the engine representing the SAGA complex. We assume that we will find at least one or two particularly promising parts of the engine. Secondly, we are examining the performance – that is, the chromatin function – of the engine and seeing what happens when we remove each of its 20 mechanical parts individually. And thirdly, we are looking at how this machine is constructed from proteins and how we can block its assembly.”
Collaborating partners in this project are the CeMM Research Centre for Molecular Medicine of the Austrian Academy of Sciences (Austria) and Harvard Medical School (USA).
Source: Press release from St. Anna Children’s Cancer Research, August 2022
#st.anna.childrenscancerresearch #childrenscancer #leukaemia #neuroblastoma #cancer #oncology #medicine #science